<DOC>
	<DOCNO>NCT02231307</DOCNO>
	<brief_summary>The aim phase III study asses SUBLIVAC FIX Birch safe effective reduce birch allergy induce symptom birch allergy medication usage .</brief_summary>
	<brief_title>SUBLIVAC FIX Birch Phase III Short-term Efficacy</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Signed informed consent Age ≥ 18 ≤65 year Moderatetosevere birch pollen induce allergic rhinitis/rhinoconjunctivitis base ARIA classification least 2 consecutive year FEV1 ( forced expiratory volume one second ) &gt; 70 % ( predict value ) patient history asthma , FEV1 &gt; 70 % PEF ( peak expiratory flow ) &gt; 80 % ( predict value ) patient without history asthma Positive SPT ( skin prick test ) birch pollen ( mean wheal diameter ≥ 3mm compare negative control ; negative control negative ; histamine control positive ( mean wheal diameter ≥ 3mm ) ) assess screen . Serum specific antibirch IgE ( immunoglobulin E ) concentration &gt; 0.7 U/ml Patients willing capable complete ediary daily birch pollen season ( ≥ 60 % compliance completion Visit 1 2 ) . A positive Nasal Provocation Test birch pollen Visit 2 ( Lebel score ≥ 6 ) document positive test within 1 year start treatment Patients sensitize symptomatic pet include regularly expose pet Specific immunotherapy ( SCIT SLIT ) birch pollen crossreacting allergen within last 5 year SPT positive ( mean wheal diameter ≥ 3mm compare negative control ; negative control negative ; histamine control positive ( mean wheal diameter ≥ 3mm ) ) patient allergen ( ) birch pollen , absence negative provocation test allergen ( ) ( within 1 year ) , expect clinically relevant symptom birch pollen season Completed unsuccessful allergenspecific immunotherapy ( SCIT SLIT ) within last 5 year ( Ongoing ) allergenspecific immunotherapy ( SCIT SLIT ) allergen ( ) study period Vaccination one week start treatment and/or updosing phase Treatment experimental product within last 3 month biologicals ( include antiIgE TNF ( tumor necrosis factor ) α treatment ) within last 6 month study Uncontrolled asthma active respiratory disease Clinically significant chronic sinusitis , ocular infection severe inflammation oral mucosa Severe immune disorder ( include autoimmune disease ) and/or disease require immunosuppressive drug Active malignancy malignant disease last 5 year Acute chronic disease opinion investigator additional risk patient , include limited following : cardiovascular insufficiency , severe unstable lung disease , endocrine disorder , clinically significant renal hepatic disease , haematological disorder Diseases contraindication use adrenaline ( e.g . hyperthyroidism , glaucoma ) Use systemic corticosteroid 4 week study Treatment systemic local βblockers Known hypersensitivity excipients ( Disodium phosphate dihydrate , Sodium dihydrogen phosphate dehydrate , aminocaproic acid , Peppermint oil , Caramel Colorant Glycerol ) A positive urine pregnancy test , lactation inadequate contraceptive method ( adequate method : oral contraceptive , IUD ( intrauterine device ) , condom use sexual relationship man ) Alcohol , drug medication abuse Lack cooperation compliance Severe psychiatric , psychological , neurological disorder Any physical mental condition precludes administration allergenspecific immunotherapy , compliance participation clinical trial Patients employee department , 1st grade relative , partner investigator Patients plan holiday outside country 7 continuous day define pollen season ( 1st March till 31st May )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>sublingual immunotherapy</keyword>
	<keyword>birch pollen</keyword>
	<keyword>allergic rhinitis / rhinoconjunctivitis</keyword>
	<keyword>efficacy</keyword>
</DOC>